Last updated: April 24, 2026
Who Supplies Capecitabine to Pharma Markets?
Capecitabine is a widely manufactured cytotoxic oral antimetabolite used in multiple oncology regimens. Supplier coverage is split into three practical buckets for downstream buyers: (1) originator and licensed producers, (2) generic API and finished-dose manufacturers, and (3) contract manufacturers (CDMO) that build tablets for brand/generic labels.
Who are the API and finished-dose suppliers for capecitabine?
API suppliers (capecitabine active pharmaceutical ingredient)
Capecitabine is typically sourced as an API from multiple global chemical/pharma manufacturers that also supply other fluoropyrimidine and oncology small molecules. The API supply chain is dominated by Chinese and Indian manufacturers for volume and cost, and by European/US-qualified producers for regulated markets.
For business planning and due diligence, API supply should be evaluated across:
- Regulatory status: WHO and stringent-regulator acceptance (EDQM/EMA/FDA inspections where applicable)
- Quality system: DMF readiness, CEP/DMF cover, controlled polymorph/process validation
- Packaging and traceability: batch-level documentation aligned to the finished-dose buyer’s requirements
Finished-dose suppliers (capecitabine tablets)
Finished-dose capecitabine is usually supplied by:
- Brand manufacturers (originator-linked supply or license holders in specific geographies)
- Generic finished-dose manufacturers that buy API and tablet-press/build in regulated facilities
- CDMOs that provide tablet manufacturing, coating, and packaging under label ownership
Because labeling and packaging specifications vary by country, procurement usually contracts by finished-dose strength, packaging form, and regional regulatory dossier readiness, not by API source alone.
What procurement documents identify capecitabine suppliers in practice?
In real sourcing workflows, capecitabine supplier identification is grounded in these documents and databases:
| Procurement artifact |
What it tells you |
Where it shows suppliers |
| DMF/ASMF |
API manufacturing sites and process controls |
Regulatory filings and permitted access databases |
| CEP (EDQM) |
Certificate-backed API quality route(s) and site(s) |
EDQM published CEP holders |
| Product dossiers |
Tablet manufacturer, packager, and sometimes API holder |
National regulator registration catalogs |
| GMP inspection outcomes |
Quality systems and recent compliance signals |
Regulator inspection repositories |
| Tender/solicitation docs |
Approved supplier lists by strength and pack |
Hospital and national tenders |
Which markets have the most supplier depth for capecitabine?
High-competition markets
- Europe: multiple EMA-registered generics; API routes vary by manufacturer and CEP/DMF coverage.
- India: deep domestic generic manufacturing; large number of tablet strengths and packaging formats.
- MENA and LATAM: often source through distributors tied to multiple generic manufacturers.
Supply constraints that concentrate suppliers
- Stringent-regulator approved API sites can be fewer than global volume producers.
- Recent GMP inspection outcomes can tighten acceptable supplier pools quickly.
What capecitabine strengths and dosage forms drive supplier selection?
Supplier qualification typically targets:
- Tablet strengths commonly purchased in oncology supply chains
- Tablet release and quality specifications (impurity profile, dissolution acceptance, stability)
- Pack formats aligned to regimen schedules (unit counts per carton)
How to map suppliers to your buyer requirements (speed-to-qualification)
For fast commercial or clinical procurement, qualification should be done in a structured supplier scoring approach:
- Regulatory eligibility
- Match to the region’s approved dossier status (market entry readiness)
- Manufacturing fit
- Tablet manufacturing capacity for your strength and packaging configuration
- Supply assurance
- Evidence of batch continuity (typical lead times, backorder risk)
- Quality package
- Batch COA, stability protocol, impurity method validation, and change control history
- Commercial terms
- Price per unit and any API-to-tablet pass-through clauses
Key Takeaways
- Capecitabine supply is split across API manufacturers, finished-dose generic/brand producers, and CDMOs, with most volume coming from large Asia-based manufacturing networks.
- In procurement, supplier identity is usually verified through DMF/ASMF, CEP holders, product dossier registrations, and GMP inspection outcomes, not marketing claims.
- The fastest route to a reliable supplier list is strength-by-strength qualification against region-specific regulatory readiness and pack configuration, since dossier and labeling constraints determine which manufacturers can actually ship.
FAQs
1) What’s the main difference between capecitabine API suppliers and tablet suppliers?
API suppliers sell the active ingredient; tablet suppliers build, coat (if applicable), package, and release the finished dose for market authorization.
2) Can the same company supply both capecitabine API and finished tablets?
Yes. Some companies produce both API and tablets, but many tablet manufacturers source API from separate upstream API sites.
3) What controls matter most when selecting capecitabine suppliers?
Regulatory dossier readiness (DMF/CEP), GMP status of the manufacturing sites, impurity profile alignment, and dissolution/stability performance for the exact strength and pack.
4) Why do suppliers differ across countries for the same capecitabine strength?
Registrations, labeling requirements, and acceptable GMP/API dossier coverage differ by jurisdiction, so the approved product list varies.
5) What is the fastest way to reduce supplier risk for capecitabine procurement?
Qualify at least two region-eligible tablet manufacturers per strength and confirm dossier/GMP coverage before contracting for volume.
References
[1] European Directorate for the Quality of Medicines & HealthCare (EDQM). Certificate of Suitability (CEP) database. https://www.edqm.eu/en/certificates
[2] U.S. Food and Drug Administration (FDA). Drug Master File (DMF) and related regulatory information. https://www.fda.gov/drugs
[3] EMA. European public assessment reports and medicines authorization information. https://www.ema.europa.eu/en/medicines
